within Pharmacolibrary.Drugs.ATC.D;

model D07AC13
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 15 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0.1 / 1000000,
    adminCount     = 1,
    Vd             = 0.22,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Mometasone is a potent synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It is commonly used topically to manage symptoms of dermatological conditions such as eczema and psoriasis, as well as intranasally for allergic rhinitis and inhaled for asthma. Mometasone furoate is approved for medical use in many countries for these indications.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for topical mometasone furoate in healthy adult individuals, as no reference with primary pharmacokinetic model reporting (describing volume of distribution, clearance, etc.) for topical, inhaled, or oral administration in humans is available in the literature.</p><h4>References</h4><ol><li><p>Spada, F, et al., &amp; Greive, KA (2018). Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids. <i>The Australasian journal of dermatology</i> 59(3) e168–e174. DOI:<a href=&quot;https://doi.org/10.1111/ajd.12762&quot;>10.1111/ajd.12762</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29411351/&quot;>https://pubmed.ncbi.nlm.nih.gov/29411351</a></p></li><li><p>Crim, C, et al., &amp; Daley-Yates, PT (2001). A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. <i>Clinical therapeutics</i> 23(9) 1339–1354. DOI:<a href=&quot;https://doi.org/10.1016/s0149-2918(01)80113-2&quot;>10.1016/s0149-2918(01)80113-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11589253/&quot;>https://pubmed.ncbi.nlm.nih.gov/11589253</a></p></li><li><p>Kaur, N, et al., &amp; Bedi, N (2018). Topical Nanostructured Lipid Carrier Based Hydrogel of Mometasone Furoate for the Treatment of Psoriasis. <i>Pharmaceutical nanotechnology</i> 6(2) 133–143. DOI:<a href=&quot;https://doi.org/10.2174/2211738506666180523112513&quot;>10.2174/2211738506666180523112513</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29788899/&quot;>https://pubmed.ncbi.nlm.nih.gov/29788899</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D07AC13;
